A positive recommendation by the DSMB to halt the study for overwhelming efficacy would likely cause a significant revaluation of the company’s shares, and while we do not think there is a great likelihood of that occurring it is something that investors should be aware of in the fourth quarter of 2016.
Zacksは有効中止はないと思ってる？
takarazimaniiku
A positive recommendation by the DSMB to halt the study for overwhelming efficacy would likely cause a significant revaluation of the company’s shares, and while we do not think there is a great likelihood of that occurring it is something that investors should be aware of in the fourth quarter of 2016.
Zacksは有効中止はないと思ってる？